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Background: The central molecule in the pathogenesis of Alzheimer’s disease (AD) is believed to be a small-sized
polypeptide – beta amyloid (Aβ) which has an ability to assemble spontaneously into oligomers. Various studies
concerning therapeutic and prophylactic approaches for AD are based on the immunotherapy using antibodies
against Aβ. It has been suggested that either active immunization with Aβ or passive immunization with anti-Aβ
antibodies might help to prevent or reduce the symptoms of the disease. However, knowledge on the mechanisms
of Aβ-induced immune response is rather limited. Previous research on Aβ1-42 oligomers in rat brain cultures
showed that the neurotoxicity of these oligomers considerably depends on their size. In the current study, we
evaluated the dependence of immunogenicity of Aβ1-42 oligomers on the size of oligomeric particles and
identified the immunodominant epitopes of the oligomers.
Results: Mice were immunized with various Aβ1-42 oligomers. The analysis of serum antibodies revealed that small
Aβ1-42 oligomers (1–2 nm in size) are highly immunogenic. They induced predominantly IgG2b and IgG2a
responses. In contrast, larger Aβ1-42 oligomers and monomers induced weaker IgG response in immunized mice.
The monoclonal antibody against 1–2 nm Aβ1-42 oligomers was generated and used for antigenic characterization
of Aβ1-42 oligomers. Epitope mapping of both monoclonal and polyclonal antibodies demonstrated that the main
immunodominant region of the 1–2 nm Aβ1-42 oligomers is located at the amino-terminus (N-terminus) of the
peptide, between amino acids 1 and 19.
Conclusions: Small Aβ1-42 oligomers of size 1–2 nm induce the strongest immune response in mice. The N-
terminus of Aβ1-42 oligomers represents an immunodominant region which indicates its surface localization and
accessibility to the B cells. The results of the current study may be important for further development of Aβ-based
vaccination and immunotherapy strategies.
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Epitope mappingBackground
Alzheimer’s disease (AD) is the most common progres-
sive neurodegenerative disease in elderly people. The
disease manifests as decline in cognitive functions and
memory loss followed by changes in personality and
mental state. It is known that while the disease evolves
the main changes take place in parts of the brain respon-
sible for the cognitive functions and memory. One of the
central molecules involved in the pathogenesis of AD is* Correspondence: indre.dalgediene@bti.vu.lt
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distribution, and reproduction in any mediumthought to be a small sized polypeptide – beta amyloid
(Aβ) which has an ability to assemble spontaneously into
oligomers [1]. It has been shown that these oligomers
depending on their size and shape have different neuro-
toxic effects on rat brain cell cultures [2]. Several thera-
peutic and prophylactic approaches based on the
anti-amyloid immunotherapy have been suggested for
AD and clinical trials have been started with either ac-
tive immunization with Aβ protein or passive
immunization with anti-Aβ antibodies. However, acute
brain tissue inflammation while using these treatments
has been reported and several clinical trials were can-
celled due to this side effect [3-5]. Therefore, betterntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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effects on the functions of immune cells may lead to the
improvement of the anti-amyloid immunotherapy.
In the current study we investigated the immuno-
logical and antigenic properties of Aβ1-42 oligomers.
We demonstrated that various Aβ1-42 oligomers differ
in their capacity to induce antibody response in experi-
mental mice. We also employed the monoclonal and
polyclonal antibodies generated against Aβ1-42
oligomers to identify their immunodominant epitopes.
Methods
Aβ1-42 oligomers
All Aβ1-42 oligomers used in this study were prepared
and characterized as described previously [2,6,7]. Syn-
thetic Aβ1-42 peptide was purchased from American
Peptide Company (Sunnyvale, California, USA).
Millipore purified water (18.2 MΩ cm) was used
throughout the work.
Briefly, broad size range (1–15 nm in size) Aβ1-42
oligomers were prepared by dissolving 0.3 mg of Aβ1-42
and incubating it in 130 μl hexafluoroisopropanol (HFIP)
for 20 min in 1.5 ml vials, followed by addition of
900 ml H2O and 20 min incubation in the resulting
HFIP/water mixture. Subsequently, the samples were
centrifuged at 12,000 g for 15 min. The solvent was
evaporated from resulting supernatant under nitrogen
stream for 5 min. Then the samples were incubated in
closed vials for 24 h with constant stirring at room
temperature.
The protocol described above was modified for produ-
cing smaller Aβ1-42 oligomeric particles. 1 mg of
peptide was dissolved in 400 μl HFIP and incubated for
30–60 min at room temperature. 100 μl of the resulting
seedless solution was added to 900 μl H2O in a
siliconized vial. After 10–20 min of incubation at room
temperature the samples were centrifuged for 15 min at
12,000 g, the supernatant was transferred to a new
siliconized tube and HFIP was evaporated in ambient air
for 1 h. Then the samples were incubated in closed vials
for 24 h in a thermostatic bath, at +20°C. The fraction of
Aβ1-42 oligomeric particles of 1–2 nm size was
produced by this protocol.
To generate larger, typically 5–10 nm Aβ1-42
oligomers, after the centrifugation the supernatant was
transferred to a nonsiliconized vial and gently purged
with nitrogen for 7 min. Then the preparation was
stirred in the same vial at ~ 500 rpm for 24 h using a
magnetic Teflon-coated stirring bar.
Finally, the Aβ1-42 monomers were formed by dissolv-
ing Aβ1-42 peptide in Millipore purified water immedi-
ately before the experiments. All solutions of prepared
Aβ1-42 oligomers were stored at −20°C no longer than
for 24 h.Shortly, to assess the size and morphology of the
preparations of Aβ1-42 oligomers, atomic force micros-
copy (AFM; Agilent 5500, Santa Clara, California, USA)
was used in the tapping mode. According to the
manufacturer’s recommendations, the probe tip
diameters were between 16 and 20 nm. About 20 μl of a
10 μM Aβ1-42 solution was spotted on freshly cleaved
mica (SPI Supplies, West Chester, Pennsylvania, USA),
incubated at room temperature for 10 min and rinsed
with Millipore purified water, then blown dry with a ni-
trogen stream. Images were acquired at scan rates be-
tween 0.5 and 1 Hz with the drive amplitude and force
kept to a minimum. The particle size was estimated by
measuring the profile of the sample within the sample
plane.
Recombinant antigens
Recombinant proteins used for the analysis of antibody
specificity by ELISA: hamster polyomavirus major capsid
protein VP1 (VP1) and human metapneumovirus
(hMPV) nucleocapsid (N) protein (hMPV N) were
described previously [8,9].
Recombinant Aβ1-40 protein fused with thioredoxin
(Trx-Aβ1-40) and expressed in E. coli was used for the
analysis of antibody reactivity by Western blot. Shortly,
thioredoxin gene was fused with Aβ1-40 gene at its N-
terminus and cloned into expression vector pET3a.
Fused protein Trx-Aβ1-40 was expressed in E. coli strain
DH5α and purified under denaturing conditions using
Ni chelating column.
Immunization of mice and generation of monoclonal and
polyclonal antibodies
BALB/c mice were bred and maintained in an animal fa-
cility at the Department of Immunology of the Centre
for Innovative Medicine (Vilnius, Lithuania). The groups
of 4 female mice aged 6–8 weeks per each antigen were
immunized with Aβ1-42 broad size range oligomers, 1–
2 nm Aβ1-42 oligomers, 5–10 nm Aβ1-42 oligomers
and Aβ1-42 monomers (non-treated peptide). Control
group of BALB/c mice (n = 4) received PBS injections.
All injections were subcutaneous. The dose was 50 μg of
oligomers or peptide per mouse. For the primary
immunizations the antigens were emulsified in complete
Freund’s adjuvant (Sigma-Aldrich, St. Louis, Missouri,
USA). The second immunization followed on day 28
with the antigens dissolved in PBS. Antiserum samples
were collected on day 14 after the first and second
immunizations and tested by an indirect enzyme-linked
immunosorbent assay (ELISA) for the presence of IgG
antibodies specific to Aβ1-42 oligomers and the
monomers. The spleen cells of the mouse with the
highest antibody titre were used for the generation of
hybridomas [10]. Three days after the boost
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with Sp2/0-Ag14 mouse myeloma cells using polyethyl-
ene glycol 1500 (PEG/DMSO solution, HybriMax,
Sigma-Aldrich). Hybrid cells were selected in growth
medium supplemented with hypoxantine, aminopterin
and thymidine (50× HAT media supplement, Sigma-
Aldrich). Samples of supernatant from wells with viable
clones were screened by an indirect ELISA. Hybridomas
secreting Aβ1-42 specific antibodies were subcloned
twice by a limiting dilution method. Hybridoma cells
were maintained in complete Dulbecco's modified Eagle's
medium (DMEM, Biochrom, Berlin, Germany) containing
15% fetal calf serum (Biochrom) and antibiotics. Antibodies
were isotyped using Monoclonal Antibody Isotyping Kit I
(HRP/ABTS) (Pierce Biotechnology, Rockford, Illinois,
USA) in accordance with the manufacturer's protocol. All
procedures involving experimental mice were performed
under controlled laboratory conditions in strict accordance
with the Lithuanian and European legislation.
Indirect enzyme-linked immunosorbent assay (ELISA)
analysis for anti-Aβ1-42 antibodies
Microtiter plates (Nunc MaxiSorp, Nunc, Roskilde,
Denmark) were coated with 100 μl/well of either Aβ1-42
oligomers or Aβ1-42 peptide dissolved in the coating
buffer (0.05 M sodium carbonate, pH 9.5) to a concentra-
tion of 5 μg/ml. For the coating with Aβ1-42 oligomers
the plates were incubated overnight at +4°C. The Aβ1-42
peptide was dried in the plates by incubating overnight
at +37°C. The coated plates were blocked with 250 μl/well
of PBS with 2% BSA for 1 h at room temperature (RT).
Then plates were rinsed twice with PBST (PBS with
0.1% Tween-20). Antiserum samples, hybridoma growth
medium or polyclonal antibodies were diluted in PBST,
added to the wells (100 μl/well) and incubated for 1 h at
RT. The plates were then incubated for 1 h with Goat
Anti-Mouse IgG (H+L)-HRP Conjugate (Bio-Rad, Hercules,
California, USA) diluted 1:5000 in PBST. The enzymatic
reaction was visualized by the addition of 100 μl of
“NeA-Blue” TMB solution (Clinical Science Products,
Mansfield, Massachusetts, USA) to each well. The reac-
tion was stopped by adding 50 μl/well of 10% sulphuric
acid solution. The optical density (OD) was measured at
450 nm (reference filter 620 nm) in a microplate reader
(Sunrise Tecan, Männedorf, Switzerland).
SDS-PAGE and western blot analysis
The samples of recombinant fused protein Trx-Aβ1-40,
E. coli DH5α lysate and HeLa lysate were boiled in a re-
ducing sample buffer and separated in 15% polyacryl-
amide gel electrophoresis (PAGE) in SDS–Tris–glycine
buffer. Proteins were visualized by staining with Coomassie
Brilliant blue (Sigma-Aldrich). The proteins from the
unstained SDS-PAGE gel were blotted onto RotiW-PVDFmembrane (Carl Roth, Karlsruhe, Germany) by semidry
electro-transfer. The membrane was blocked with 2%
milk powder in PBS for 2 h at RT and rinsed with PBST.
The membrane was then incubated for 1 h at RT with
primary antibodies at working dilution in PBST with 2%
milk powder and subsequently incubated with Goat
Anti-Mouse IgG (H+L)-HRP Conjugate (Bio-Rad) diluted
1:4000 in PBST with 2% milk powder. The enzymatic
reaction was developed using 4-chloro-1-naphtol and
H2O2 (Fluka, Milwaukee, Wisconsin, USA). For the
analysis of antisera, they were diluted 1:1000 in PBST.
For the analysis of monoclonal antibodies, undiluted
hybridoma supernatant was used.
Characterization of Aβ1-42 epitopes recognized by
polyclonal and monoclonal antibodies
For the epitope mapping, the collection of synthetic,
overlapping, Aβ1-42 spanning, 13 amino acids (aa) in
length and linked with biotin-SGSG at the N-terminus
peptides was used (Metabion, Martinsried, Germany).
Microtiter plates (Nunc MaxiSorp, Nunc) were coated
with streptavidin dissolved in deionized H2O (2 μg/ml)
by incubating overnight at +37°C. The coated plates
were blocked with 2% BSA in PBS. Synthetic peptides
with biotin were added to the wells diluted in PBST at
concentrations recommended by the manufacturer and
incubated for 1 h at RT. Hybridoma supernatant (un-
diluted) and polyclonal antibodies (diluted 1:1000 in
PBST) were added to the wells (100 μl/well) and
incubated for 1 h at RT. The plates were incubated for
1 h with Goat Anti-Mouse IgG (H+L)-HRP Conjugate
(Bio-Rad) diluted 1:5000 in PBST. The enzymatic reac-
tion was visualized with TMB as described above.
Results
Immune response to Aβ1-42 oligomers in mice
To investigate the immunogenicity of various Aβ1-42
oligomer forms, four groups of BALB/c mice were
exploited. Each group of mice was injected with the
same doses (50 μg per mouse) of the antigens: broad size
range Aβ1-42 oligomers, Aβ1-42 oligomers with particle
size of 1–2 nm, Aβ1-42 oligomers with 5–10 nm particle
size and Aβ1-42 monomers. The levels of antigen-
specific IgG antibodies in the antiserum samples were
estimated by calculating the antibody titres in ELISA
against the antigens used for the immunization. After
the first immunization, the titres of antigen-specific IgG
antibodies in all groups of immunized mice did not
exceed 1:100 (data not shown). Although the adjuvant
was used for the primary immunization to enhance
the immune response, the adjuvant might have also
disrupted the oligomeric structure of the antigens.
After the secondary immunization applied without an
adjuvant there was a significant difference in antibody
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The highest antibody response was observed in mice
immunized with 1–2 nm Aβ1-42 oligomers. The titres
of antigen-specific IgG were almost 3 times higher in
this group of mice as compared to that immunized
with broad size range oligomers (1:2000 and 1:700, re-
spectively). In contrast, the titres of antigen-specific
IgG in the group of mice immunized with 5–10 nm
Aβ1-42 oligomers did not exceed 1:500. Thus, the
series of the strongest Aβ1-42 immunogens varied from
1–2 nm oligomers to the broad size range oligomers and
5–10 nm oligomers. As expected, Aβ1-42 monomers
demonstrated the weakest immunogenic properties giving
antibody titres about 1:200 (Figure 1). Moreover, antisera
raised against 1–2 nm Aβ1-42 oligomers showed in ELISA
4 times lower titres with Aβ1-42 monomers as compared
to 1–2 nm Aβ1-42 oligomers: 1:500 and 1:2000, respect-
ively. Antisera collected from the control group of mice
injected with PBS alone showed only background level
activity with antibody titres less than 1:20. These results
demonstrated that Aβ1-42 oligomeric structure is
important in the activation of B cells and induction
of the antibody response. To evaluate the involvement
of helper T cells in B cell activation, the subclass distri-
bution of antigen-specific IgG antibodies in the pool
of antisera of mice immunized with 1–2 nm Aβ1-42
oligomers was analysed. The majority of the IgG anti-
bodies (57%) raised against 1–2 nm Aβ1-42 oligomers
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Generation of monoclonal antibodies against Aβ1-42
oligomers
Spleen cells of mice with the highest antibody titre
induced by 1–2 nm Aβ1-42 oligomers were used to gen-
erate the monoclonal antibodies (MAbs). One stable
hybridoma clone 11E12 producing Aβ1-42-specific MAb
of IgG2b subtype was generated. An indirect ELISA with
different Aβ1-42 oligomers and the monomers revealed
a strong reactivity of the MAb 11E12 with 1–2 nm Aβ1-
42 oligomers: titres of antigen-specific antibodies in the
hybridoma supernatant were 1:2000. In contrast, the re-
activity of the MAb 11E12 with 5–10 nm oligomers and
the monomeric peptide was significantly lower: titres in
ELISA were 1:80 and 1:50, respectively (data not shown).
The specificity of the MAb to the Aβ1-42 sequence was
also confirmed by Western blot analysis of recombinant
fused protein Trx-Aβ1-40. The MAb 11E12 reacted spe-
cifically with recombinant Trx-Aβ1-40 but did not react
with E. coli DH5α lysate and HeLa cell lysate used as
negative controls (Figure 2A). Antiserum of the mouse
immunized with 1–2 nm Aβ1-42 oligomers and used for
the generation of monoclonal antibody 11E12 also
showed reactivity with recombinant fused protein Trx-
Aβ1-40 (Figure 2B). In contrast, pools of antisera raised
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Table 1 Distribution of the subtypes of IgG antibodies
raised against 1–2 nm Aβ1-42 oligomers, expressed in
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or no reactivity with recombinant fused protein Trx-
Aβ1-40 (data not shown).
Mapping of Aβ1-42 epitopes recognized by polyclonal
and monoclonal antibodies
To investigate the antigenic structure of Aβ1-42
oligomers, we have employed a series of overlapping 13
aa-long synthetic peptides spanning the Aβ1-42 se-
quence (Table 2). The MAb 11E12 reacted exclusively
with the peptide representing the N-terminal sequence
(aa 1–13, Table 2). Antiserum of the mouse immunized
with 1–2 nm Aβ1-42 oligomers and used for the gener-
ation of monoclonal antibody 11E12 showed strong re-
activity exclusively with peptides #1 and #2 representing
the N-terminus of Aβ1-42 protein (aa 1–19). Pools of
antisera raised against the broad size range Aβ1-42Figure 2 Reactivity of monoclonal antibody 11E12 (A) and
antiserum of the mouse immunized with 1–2 nm Aβ1-42
oligomers (B) in Western blot. C – Coomasie blue-stained gel.
Lane 1, recombinant fused protein Trx-Aβ1-40; lane 2, E. coli DH5α
cells lysate; lane 3, HeLa cells lysate. Lane M, prestained protein
molecular weight marker: 130, 100, 70, 55, 40, 25, 15 kDa
(Fermentas/Thermo Scientific, Vilnius, Lithuania). The position of
recombinant fused protein Trx-Aβ1-40 (molecular weight in a range
of 16–20 kDa) is indicated by a dot.oligomers and 5–10 nm Aβ1-42 oligomers showed a
week positive reaction also with the N-terminal peptide
#1 and did not show any reactivity with other peptides.
Thus, regardless of the form of Aβ1-42 oligomers the N-
terminus was identified as an immunodominant region
of Aβ1-42 oligomers.
Discussion
The attempts to use active immunization with Aβ or
passive immunization with anti-Aβ antibodies represent
promising new strategies in the immunotherapy of AD.
However, the results of previous preclinical and clinical
studies of AD immunotherapy were controversial [3,5].
In some cases acute brain inflammation occurred [3]. A
number of questions on the origin and mechanism(s) of
these unwanted side effects still remains unanswered. It
is not yet known what impact on the pattern of the im-
mune response various aggregate forms of Aβ may have.
To elucidate the mechanisms of anti-Aβ immune re-
sponse, naturally occurring antibodies against Aβ have
been investigated [11]. It is also possible to focus on
various artificial Aβ aggregate forms and gain informa-
tion on their immunogenic and antigenic properties
using laboratory animal models.
In the current study, we have investigated the im-
munogenicity of various Aβ1-42 oligomers including the
small-sized oligomers that were shown to be highly
neurotoxic in vitro [2,12]. The analysis of the humoral
immune response in mice immunized with different
Aβ1-42 oligomers revealed that their immunogenicity
strongly depends on the size of oligomeric particles so
that the smallest Aβ1-42 oligomers with particle size of
1–2 nm (corresponding to dimers – pentamers [2]) were
the strongest immunogens in comparison with 5–10 nm
oligomers or broad size range oligomers. Moreover, the
analysis of IgG subtypes in the sera of immunized mice
revealed IgG2a as the major IgG subclass of Aβ-specific
antibodies thus suggesting the predominant role of Th1
cells in B cell activation (Table 1). On the other hand, it
cannot be excluded that IgG subtype distribution was
influenced by the use of adjuvant since Aβ1-42
oligomers were non-immunogenic in mice when applied
without it. Previous studies on the neurotoxicity of dif-
ferent Aβ1-42 oligomers in rat brain cell cultures
revealed that the most neurotoxic Aβ1-42 oligomers are
of size 1–2 nm [2]. Thus, the smallest 1–2 nm Aβ1-42
oligomers possess both high neurotoxicity and immuno-
genicity. The nature of the link between those two prop-
erties of the smallest 1–2 nm Aβ1-42 oligomers remains
still to be elucidated.
Our study demonstrated that the N-terminal part of
the Aβ1-42 oligomers was accessible to B cells in active
immunization and induced the development of Aβ1-42
specific antibodies. The obtained data on the surface-
Table 2 Epitope mapping of Aβ1-42 monoclonal antibody (MAb) 11E12 and polyclonal antisera based on their
immunoreactivity with overlapping peptides spanning Aβ1-42 sequence
Peptide
No.
aa sequence The reactivity of peptides with different antibodies in ELISA:
MAb
11E12
Antisera to broad size range
oligomers
Antisera to 1–2 nm
oligomers
Antisera to 5–10 nm
oligomers
1 (aa 1–13) DAEFRHDSGYEVH ++ + ++ +
2 (aa 7–19) DSGYEVHHQKLVF - - + -
3 (aa 13–
25)
HHQKLVFFAEDVG - - - -
4 (aa 19–
31)
FFAEDVGSNKGAI - - - -
5 (aa 25–
37)
GSNKGAIIGLMVG - - - -
6 (aa 31–
42)
IIGLMVGGVVIA - - - -
Every next peptide was starting with the same 7 aa from the previous one. The last peptide was 12 aa in length. The interaction between peptides and antibodies
in an indirect ELISA is expressed as “++” – strong (OD > 1.0), “+” – weak (1.0 > OD > 0.25) and “-“– none (OD < 0.25).
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are in line with previous studies proposing that the as-
sembly of oligomers starts at the middle and carboxy-
terminal (C-terminal) parts of the Aβ [13,14]. Therefore,
active immunization with Aβ oligomers may lead to gen-
eration of N-terminus specific antibodies. The immuno-
genicity of the N-terminal part of Aβ1-42 oligomers also
indicates that the oligomers tend to maintain their struc-
tural features during the interactions with B cells. This
presumption is based on the fact that both monoclonal
antibody 11E12 and polyclonal antisera raised against 1–
2 nm Aβ1-42 oligomers showed higher reactivity with
Aβ1-42 oligomers as compared to Aβ1-42 monomers.
On the other hand, both the antibody 11E12 and poly-
clonal antisera were reactive with synthetic peptides
representing N-terminal linear epitopes of Aβ1-42 thus
suggesting that conformational epitopes were present
but not immunodominant in Aβ1-42 oligomers. Previous
studies have demonstrated that passive immunization
with a monoclonal antibody directed against the central
domain of Aβ peptide (13–28 aa) was effective in redu-
cing brain Aβ burden by promoting CNS and plasma
Aβ clearance in mice [15,16]. Clinical trials on active
immunization with Aβ1-42 peptide (AN1792) revealed
that plaque load has decreased, however this decrease
was insufficient to improve the cognitive functions of
AD patients [5]. It has been shown that the peptide
AN1792 induced antibodies against the N-terminus of
Aβ protein (1–8 aa) [17]. Thus, the Aβ oligomers used
in our study resemble immunogenic properties of those
explored in other immunization studies. In contrast,
naturally occurring anti-Aβ antibodies have been shown
to be mainly directed to the middle and/or C-terminal
epitopes of Aβ protein and to inhibit the tendency of Aβ
protein to fibrillate thereby blocking its neurotoxicity
[18-20]. The latest studies have shown that thesenaturally occurring antibodies bind to early
oligomerization products and interfere with this process
[11]. In contrast, antibodies raised against the N-terminus
of Aβ protein may not necessarily interfere with the
oligomerization of Aβ protein. These studies suggest that
further assessments should be made for the development
of new immunotherapy tools against AD using antibodies
targeting either the middle or C-terminal part of Aβ
oligomers.
In summary, our study provides new data on the
immunogenicity of small-sized Aβ1-42 oligomers and
demonstrates their capability to induce antibodies directed
predominantly to the N-terminal region of Aβ protein.
Conclusions
Small Aβ1-42 oligomers of size 1–2 nm induce the
strongest immune response in mice. The N-terminus of
Aβ1-42 oligomers represents an immunodominant re-
gion which indicates its surface localization and accessi-
bility to the B cells. The results of the current study may
be important for further development of Aβ-based vac-
cination and immunotherapy strategies.
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